-
Kitsap Respiratory Illness Report: March 17-23
Advisory or Update, Communicable Disease and Immunization Update, Communicable Disease Data Report, COVID-19, Health Advisory, Infection Control, Influenza, Influenza Update, News and Alerts, News and Update, Prevention, Provider Resources, Respiratory Illness Report, Respiratory Illness ReportClick here to access week 12 of the Kitsap Respiratory Illness Report. In week ending on March 23, local indicators for influenza remained elevated. Indicators for COVID-19 and respiratory syncytial virus (RSV) remained low. 0.7% of emergency department (ED) visits were attributable to influenza, and fewer than 10 visits were attributable to COVID-19 and to RSV.…
-
Health Advisory: COVID-19 Updates
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Emerging Diseases and Conditions, Health Advisory, Health Alert, Immunizations, News and Alerts, Notifiable Conditions, Novel Coronavirus, Provider Resources, VaccineActions Requested Discuss a fourth dose of COVID-19 vaccine with immunocompromised patients. The Centers for Disease Control and Prevention (CDC) recommends people ages 5 and older who are moderately or severely immunocompromised should get an additional primary shot (third dose) of an mRNA vaccine 28 days after receiving their second dose. An additional primary shot…
-
Kitsap Respiratory Illness Report January 23 – January 29, 2022
Click here to access the latest Kitsap Respiratory Illness Report: 1.23.22 – 1.29.22.
-
02/01/22 Health Advisory: FDA Provides Full Approval For Spikevax
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Health Advisory, Notifiable Conditions, Provider Resources, UncategorizedCOVID-19 Updates for Providers Requested actions Be aware, U.S. Food and Drug Administration (FDA) granted full authorization to Moderna COVID-19 vaccine for people 18 years or older. Evidence shows the vaccine is safe and effective and manufactured with high quality. The vaccine will now be called Spikevax but has the same formulation as emergency use…
-
Health Advisory: COVID-19 Updates to Transferring Residents Between Long-Term Care and other Healthcare Settings
Advisory or Update, COVID-19, Emerging Diseases and Conditions, Health Advisory, Health Alert, News and Alerts, News and Update, Novel CoronavirusActions Requested Be aware, Washington Department of Health updated the Interim Guidance for Transferring Residents between Long-Term Care and other Healthcare Settings to address health care system capacity shortages. The interim guidance, effective January 21, 2022 until February 18, 2022, waives guidance asking facilities to pause admissions with identified healthcare personnel or facility acquired COVID-19…
-
Kitsap Respiratory Illness Report January 9 – January 15, 2022
Click here to access the latest Kitsap Respiratory Illness Report: 1.9.22 – 1.15.22.
-
Kitsap Respiratory Illness Report January 2 – January 8, 2022
Click here to access latest Kitsap Respiratory Illness Report: 1.2.22 – 1.8.22.
-
Health Advisory: CDC updated antiviral guidance
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Health Advisory, Health Alert, Immunization, News and Alerts, News and Update, Notifiable Conditions, Novel Coronavirus, Provider Resources, SchoolsActions Requested Be aware, Centers for Disease Control and Prevention (CDC) updated its COVID-19 monoclonal antibody treatment recommendations. Sotrovimab monoclonal antibody formulation retains significant efficacy against Omicron, the dominant circulating variant. Other monoclonal antibody formulations under emergency use authorization (EUA)—bamlanivimab and etesevimab and casirivimab and imdevimab—lack clinical benefit against Omicron and should not be used…
-
01/06/22 Health Advisory: Booster Eligibility Expanded
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Health Advisory, Immunizations, News and Alerts, Notifiable Conditions, Provider ResourcesCOVID-19 Updates for Providers Requested actions Be aware, Centers for Disease Control and Prevention (CDC) endorsed Advisory Committee on Immunization Practices’ (ACIP’s) decision to strongly recommend a single Pfizer COVID-19 vaccine booster dose for people 12–17 years old at least 5 months after their primary series. This expands the age of booster access and strengthens…
-
01/04/22 Health Advisory: CDC updated antiviral guidance
Advisory or Update, COVID-19, Health Advisory, News and Alerts, Notifiable Conditions, Provider ResourcesCOVID-19 Updates for Providers Requested actions Be aware, Centers for Disease Control and Prevention (CDC) updated its COVID-19 monoclonal antibody treatment recommendations. Sotrovimab monoclonal antibody formulation retains significant efficacy against Omicron, the dominant circulating variant. Other monoclonal antibody formulations under emergency use authorization (EUA)—bamlanivimab and etesevimab and casirivimab and imdevimab—lack clinical benefit against Omicron and…
-
Kitsap Respiratory Illness Report December 19 – December 25, 2021
Click here to access the latest Kitsap Respiratory Illness Report: 12.19.21 – 12.25.21.
-
Health Advisory: COVID-19 Updates for Providers – New I&Q Guidance, FDA grants EUA to Molnupiravir
COVID-19, Emerging Diseases and Conditions, Health Advisory, Health Alert, Infection Control, News and AlertsActions Requested Be aware, Centers for Disease Control and Prevention (CDC) issued new isolation and quarantine (I&Q) guidance for healthcare workers (HCWs). The guidance is complex and varies based on vaccination status, level of exposure and level of crisis in the community. Carefully review the new guidance for details. Following exposure, CDC recommends: Boosted HCWs…